Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

I-Mab ADR (IMAB)

I-Mab ADR (IMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 146,071
  • Shares Outstanding, K 80,702
  • Annual Sales, $ 3,890 K
  • Annual Income, $ -206,440 K
  • 60-Month Beta 1.11
  • Price/Sales 37.31
  • Price/Cash Flow N/A
  • Price/Book 0.61
Trade IMAB with:

Options Overview Details

View History
  • Implied Volatility 153.09% ( -157.19%)
  • Historical Volatility 28.88%
  • IV Percentile 69%
  • IV Rank 10.21%
  • IV High 1,126.44% on 09/19/23
  • IV Low 42.39% on 06/16/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 443
  • Open Int (30-Day) 542

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.51
  • Number of Estimates 1
  • High Estimate -0.51
  • Low Estimate -0.51
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7550 +3.13%
on 04/02/24
1.9700 -8.12%
on 03/26/24
-0.0500 (-2.69%)
since 03/25/24
3-Month
1.5100 +19.87%
on 02/23/24
2.0800 -12.98%
on 02/07/24
unch (unch)
since 01/25/24
52-Week
1.1600 +56.03%
on 09/25/23
3.4500 -47.54%
on 05/16/23
-1.3300 (-42.36%)
since 04/25/23

Most Recent Stories

More News
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐...

IMAB : 1.8100 (unch)
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

IMAB : 1.8100 (unch)
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells....

IMAB : 1.8100 (unch)
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

IMAB : 1.8100 (unch)
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's...

IMAB : 1.8100 (unch)
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting...

IMAB : 1.8100 (unch)
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

IMAB : 1.8100 (unch)
MSCI ESG Updated I-Mab to "A" Rating

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

IMAB : 1.8100 (unch)
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

IMAB : 1.8100 (unch)
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks

IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in...

IMAB : 1.8100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China.

See More

Key Turning Points

3rd Resistance Point 1.8500
2nd Resistance Point 1.8300
1st Resistance Point 1.8200
Last Price 1.8100
1st Support Level 1.7900
2nd Support Level 1.7700
3rd Support Level 1.7600

See More

52-Week High 3.4500
Fibonacci 61.8% 2.5752
Fibonacci 50% 2.3050
Fibonacci 38.2% 2.0348
Last Price 1.8100
52-Week Low 1.1600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar